Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pacific Edge Limited ( (NZ:PEB) ) just unveiled an announcement.
Pacific Edge has announced that it will release its full-year financial results for the 12 months to 31 March 2026 on 25 May 2026, before 10 a.m. New Zealand time. The disclosure will be followed by an investor and analyst conference call and webcast, signalling continued engagement with capital markets and providing stakeholders an opportunity to question management on performance and strategy.
The company’s flagship Cxbladder tests are supported by more than two decades of research and over 25 peer-reviewed publications, with one product included in the American Urological Association’s Microhematuria Guideline. With adoption by more than 5,000 urologists in the U.S. and broad accessibility through public healthcare in New Zealand, the upcoming results and briefing will be closely watched as indicators of commercial traction and the effectiveness of ongoing clinical and market expansion initiatives.
More about Pacific Edge Limited
Pacific Edge Limited is a global cancer diagnostics company focused on developing and commercialising bladder cancer diagnostic and prognostic tests for patients with hematuria or under surveillance for recurrent disease. Headquartered in Dunedin, New Zealand, it delivers its Cxbladder suite of non-invasive genomic urine tests through CLIA-certified laboratories in New Zealand and the U.S., with availability across the U.S., Australasia, Israel, Asia and South America.
YTD Price Performance: -5.95%
Average Trading Volume: 601,394
Technical Sentiment Signal: Hold
Current Market Cap: N$177.9M
For an in-depth examination of PEB stock, go to TipRanks’ Overview page.